{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"37","upperLimit":"77","value":"57"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"}],"units":"Participants"}],"description":"Percentage of patients who experienced partial nephrectomy in lieu of nephrectomy in 25% of children with unilateral tumors and aniridia, Beckwith-Wiedemann syndrome (BWS), hemihypertrophy or other overgrowth syndromes, by using prenephrectomy 2-drug chemotherapy induction with vincristine and dactinomycin.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients start with either 2 drug or three drug chemotherapy (Regimen VA, VAD) and are evaluated a 6 and 12 weeks for feasibility of undergoing a partial nephrectomy. At week 12 definitive surgery takes place followed by chemotherapy.\n\nDactinomycin: Given IV\n\nDoxorubicin Hydrochloride: Given IV\n\nRadiation Therapy: Undergo radiation therapy\n\nTherapeutic Conventional Surgery: Undergo surgical resection\n\nVincristine Sulfate: Given IV","id":"OG000","title":"Arm 2 (Unilateral High Risk Tumors Bilaterally Predisposed)"}],"paramType":"NUMBER","populationDescription":"Eligible and evaluable patients with unilateral high risk tumors who had partial or complete nephrectomy. 16 total patients were excluded (1 ineligible, 1 inevaluable, 1 violated protocol, and 13 did not have definitive surgery (partial or complete nephrectomy).","reportingStatus":"POSTED","timeFrame":"12 weeks from study entry","title":"Percentage of Patients Who Experienced Partial Nephrectomy After Preoperative Chemotherapy","type":"PRIMARY","unitOfMeasure":"percentage of patients"}